| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Barinthus Biotherapeutics plc$0.64
0 (-0.02%)
C 43Pipeline Score Undervalued Pharma · Clinical
Market Cap
28.06 M
EPS
-1.29
P/E Ratio
-
Value Trade
2.69 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.59 M
Operating CF
-3.37 M
Total Assets
92.14 M
Total Liabilities
25.66 M
Equity
66.40 M
D/E Ratio
12,345
-5.89 %
Week
12.96 %
1 Month
16.22 %
3 Month
0.7 %
6 Month
-95.57 %
5 Year
-94.96 %
All Time
Cash Data
Cash Position
65.86 M
Monthly Burn
1.12 M
Runway
56.3 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
2.51 K
52 Week Range
0.51 - 2.92
% held by Insiders
3.48 %
% held by Institutions
19.28 %
Enterprise Value
-28.04 M
Total Shares
40.85 M
Short %
0.06 %
Float Shares
39.43 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Barinthus Biotherapeutics plc
205Total events
2Upcoming
62Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
Event history 203
Q3 2026
◆Topline ReadoutVTP-1000Clinical Data
Multiple ascending dose data from Phase 1 AVALON trial expected in H2 2026
celiac diseasesource ↗
Jun 2026
◆AcquisitionCorporate
Proposed combination with Clywedog Therapeutics progressing towards closing
Q2 2026
2026
◆Oral PresentationVTP-1000Presentation
Data presentation at a scientific conference in 2026
celiac diseasesource ↗
Dec 10, 2025
▲Safety Data UpdateVTP-1000Clinical Data
SAD portion completed: VTP-1000 well tolerated with no treatment-related SAEs and dose-dependent pharmacological effect observed
celiac diseasesource ↗
Drug Pipeline Intelligence
C43
Pipeline Score $313M
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored11.1x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 912)
Percentile RankBarinthus Biotherapeutics plc carries a moderate pipeline score (43/100), with $1.3B risk-adjusted pipeline value, led by MVA-NP+M1 in Influenza (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MVA-NP+M1 Monoclonal antibody | Influenza | Phase 2 | NCT03883113 | 30% | $608M | COMPLETED | 145 | - | - | Apr 17, 2020 | - | Mar 18, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VTP-1000 | Celiac Disease | Phase 1 | 2025-12-10 | well tolerated with no treatment-related SAEs; dose-dependent pharmacological effect observed; enrolled 18 patients in three placebo-controlled cohorts of ascending doses Read More | Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease Read More | |
VTP-1000 | Celiac Disease | Phase 1 | 2025-12-10 | well tolerated with no treatment-related SAEs; dose-dependent pharmacological effect observed; enrolled 18 patients in three placebo-controlled cohorts of ascending doses Read More | Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease Read More | |
VTP-1000 | Celiac Disease | Phase 1 | 2025-12-10 | well tolerated with no treatment-related SAEs; dose-dependent pharmacological effect observed; enrolled 18 patients in three placebo-controlled cohorts of ascending doses Read More | Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BRNS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BRNS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BRNS▲ +8.4%on this news
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics announced its Q1 2026 financial results, highlighting progress on its merger with Clywedog Therapeutics and advancements in the Phase 1 AVALON trial of VTP-1000 for celiac disease. The company reported a net loss of $5.5 million but emphasized the potential of its pipeline and the expected benefits from the merger. Key data from ongoing trials is anticipated in the latter half of 2026.
Read more →BRNS▲ +8.4%on this news
Document Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in
Barinthus Biotherapeutics has reported its financial results for Q1 2026 and outlined its corporate developments, notably regarding the proposed merger with Clywedog Therapeutics. The merger aims to create a differentiated portfolio focused on autoimmune and metabolic diseases, with significant clinical milestones expected within the next 18 months. VTP-1000, Barinthus's lead candidate for treating celiac disease, shows progress in clinical trials with critical data anticipated in late 2026. Additionally, the company has made key executive changes and is optimizing its financial resources for continued research and development activities.
Read more →BRNSBarinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics reported its financial results for 2025, highlighting a proposed merger with Clywedog Therapeutics to enhance its clinical portfolio. The company is progressing with the Phase 1 AVALON trial of VTP-1000 for celiac disease, with data expected in late 2026. Despite a net loss of $66.5 million, the firm anticipates a strong cash runway through 2027, supported by existing and new investors.
Read more →BRNSDocument Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clini
Barinthus Bio reported its financial results for 2025, highlighting a proposed merger with Clywedog Therapeutics to create a company focused on autoimmune and metabolic diseases. The Phase 1 trial for its lead candidate, VTP-1000, shows promising results in celiac disease, with additional data expected in the latter half of 2026. Despite these positives, the company experienced increased net losses and general expenses during the year, alongside a notable impairment of intangible assets. The merger aims to strengthen Barinthus's clinical pipeline and leverage its investor base.
Read more →BRNSBarinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Barinthus Bio has announced promising results from the Phase 1 AVALON clinical trial for its investigational therapy VTP-1000 aimed at treating celiac disease. The single ascending dose portion of the trial demonstrated a well-tolerated profile with no serious adverse events and showed a dose-dependent pharmacological effect. The multiple ascending dose segment, which includes a gluten challenge, is currently ongoing. The company's proprietary SNAP-TI platform aims to promote immune tolerance to gluten, with potential for significant patient benefit.
Read more →BRNSDocument Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharma
Barinthus Bio has provided an update on its first-in-human Phase 1 AVALON trial of VTP-1000 for celiac disease, reporting promising initial results. The single ascending dose (SAD) portion showed VTP-1000 was well tolerated with no treatment-related serious adverse events. Additionally, a dose-dependent pharmacological effect was observed. The multiple ascending dose (MAD) portion is ongoing, including a gluten challenge, with data expected in 2026.
Read more →BRNS▼ -10.1%on this news· ran to -32% by day 3
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc (NASDAQ: BRNS) announced its financial results for Q3 2025, highlighting a proposed merger with Clywedog. CEO Bill Enright emphasized the merger's potential to create a stronger company by diversifying its pipeline in metabolic and autoimmune diseases. The company is focused on advancing therapies for conditions like Type 1 and Type 2 diabetes and celiac disease.
Read more →BRNS▼ -10.1%on this news· ran to -32% by day 3shared move
Document Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments S ingle ascending dose data readout for VTP-1000 expected before the end of 2 025 Enrollment advancing in multiple
Barinthus Bio has reported its third quarter 2025 financial results and updated investors on its corporate developments, including the anticipated readout of VTP-1000 data by the end of 2025. The company has proposed a merger with Clywedog Therapeutics to enhance its pipeline and attract high-caliber investors. While the company reported a net loss of $14.6 million for the quarter, it emphasized a cash position that supports operations through 2027, alongside ongoing clinical trials with VTP-1000 and other therapeutic programs. The merger is expected to close in the first half of 2026, further advancing its capabilities in treating metabolic and autoimmune diseases.
Read more →BRNSBarinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
Barinthus Biotherapeutics and Clywedog Therapeutics have announced a merger agreement to form a new company focused on metabolic and autoimmune diseases. The merger will create a diversified pipeline with clinical-stage candidates, including therapies for Type 1 and Type 2 diabetes and celiac disease. The transaction is expected to close in the first half of 2026, pending shareholder and regulatory approvals.
Read more →BRNS▲ +10.7%on this news
Document Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments The final cohort of the single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD dat
Barinthus Bio has announced its second quarter 2025 financial results alongside updates on its clinical trials. The final cohort of the Phase 1 AVALON trial for its immunotherapy VTP-1000 has been initiated, with data readout expected in Q4 2025. The company reported a net loss of $21.1 million for the quarter, despite maintaining a cash runway projected to last into 2027. Overall, the progress in clinical development and maintained financial guidance signals a positive outlook, although the continued losses raise concerns about long-term viability.
Read more →BRNS▲ +10.7%on this news
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments The final cohort of the single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD data readout
Barinthus Biotherapeutics plc (NASDAQ: BRNS) released its financial results for Q2 2025, reporting the start of the final cohort in the Phase 1 AVALON trial along with the initiation of its multiple ascending dose (MAD) segment. The company's lead candidate, VTP-1000, aims to provide immunotherapy solutions for celiac disease. Their cash runway is assured until 2027, emphasizing financial stability amidst ongoing development activities, yet they reported an increasing accumulated deficit.
Read more →BRNSDocument Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dos
Barinthus Bio has reported its financial results for the first quarter of 2025, highlighting significant advancements in their immunotherapy pipeline, particularly VTP-1000 for celiac disease. The Phase 1 single ascending dose data for this treatment is anticipated in Q3 2025, while multiple ascending doses are set to begin in the latter half of the year. Additionally, encouraging results from Phase 2 trials for chronic hepatitis B are expected to attract partnerships. Despite a decline in cash reserves and R&D expenses, the company maintains a financial outlook projected to sustain operations until 2027.
Read more →BRNSBarinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc reported its financial results for Q1 2025, highlighting progress in its lead immunotherapy asset VTP-1000 for celiac disease. The company anticipates releasing data from Phase 1 of VTP-1000 soon and starting multiple ascending dose trials later in 2025. Additionally, promising results from its VTP-300 and ongoing clinical trials were presented at the EASL Congress, indicating potential advancements in the treatment of chronic hepatitis B virus. While financial metrics showed increased administrative expenses and a decline in cash reserves, the company projects sufficient funding through 2027 to support its research and development efforts.
Read more →BRNSBarinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc has reported its financial results for the year ended December 31, 2024, highlighting a strategic shift towards immunologic and inflammatory diseases. The company is advancing its immunotherapy candidate VTP-1000 for celiac disease, with initial clinical data expected in Q3 2025, and has shown promising Phase 2 results for VTP-300 in chronic hepatitis B. The company's current financial outlook suggests it has sufficient resources projected to fund operations into 2027 despite a decrease in cash reserves.
Read more →BRNSDocument Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseases
Barinthus Bio has reported its financial results for 2024, highlighting a strategic transformation aimed at focusing on immunology and inflammatory diseases. The company is advancing its lead asset, VTP-1000, for celiac disease, with clinical data expected in 2025. Also, promising interim results from their chronic hepatitis B (VTP-300) trials suggest strong market positioning. Barinthus Bio's cash reserves are projected to sustain operations through 2027, supporting ongoing clinical developments.
Read more →BRNS▼ -9.6%on this news
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Barinthus Biotherapeutics has announced a strategic focus on immunology and inflammation, aiming to enhance its SNAP-TI platform for autoimmune diseases. The company plans to release Phase 1 clinical data for VTP-1000 in celiac disease by mid-2025. Despite achieving a functional cure in some chronic hepatitis B patients, Barinthus will seek partners for VTP-300 development and has decided to reduce its workforce significantly.
Read more →BRNS▼ -9.6%on this newsshared move
Document Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I I) and Provides a Financial Update Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025 Postponing furt
Barinthus Bio has announced a strategic pivot focusing on immunology and inflammation, prioritizing the development of VTP-1000 for celiac disease with Phase 1 results expected in mid-2025. The company will postpone further clinical advancement of VTP-300 in chronic hepatitis B until a suitable partner is found. Additionally, a workforce reduction of approximately 65% will extend the cash runway to early 2027 but raises concerns regarding operational efficiency. Future corporate milestones include key data releases scheduled for 2025.
Read more →BRNS▲ +8.9%on this news
Document Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer OXFORD, United Kingdom and GERMANTOWN, MD, United States
Barinthus Bio has announced the promotion of Geoffrey Lynn, M.D., Ph.D., to Chief Scientific Officer, effective December 1, 2024. This transition follows the decision of his predecessor, Nadge Pelletier, to seek other opportunities. Dr. Lynn, co-inventor of the SNAP-TI technology, brings over 15 years of experience in immunotherapeutic R&D. Barinthus Bio is currently advancing products targeting chronic infectious diseases and autoimmunity, including ongoing clinical trials for several candidates.
Read more →BRNS▲ +8.9%on this news
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Barinthus Biotherapeutics announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer, effective December 1, 2024. He succeeds Nadège Pelletier, who has been pivotal in Barinthus's R&D efforts, particularly in developing therapies for autoimmune diseases. Dr. Lynn, a co-inventor of the SNAP-TI technology, is expected to continue the company's momentum as it advances its promising pipeline, including candidates for chronic hepatitis B and celiac disease. The transition is set to occur smoothly, with Dr. Pelletier remaining during the change.
Read more →BRNS▼ -29.7%on this news
Document Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B Significantly greater mean declines
Arbutus Biopharma and Barinthus Bio announced promising preliminary findings from the IM-PROVE II clinical trial, showing significant HBsAg loss in participants receiving a combination treatment of imdusiran, VTP-300, and low-dose nivolumab. Notably, 23% of these subjects reached HBsAg loss by Week 48. The study suggests increased effectiveness of this combination therapy compared to previous treatment groups. Importantly, the treatment was well tolerated with no immune-related adverse events reported.
Read more →BRNS▼ -29.7%on this news
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Barinthus Biotherapeutics announced promising results from its Phase 2b HBV003 clinical trial for chronic hepatitis B. Key findings include eight participants achieving HBsAg loss and two meeting criteria for functional cure. The data suggests that the combination of VTP-300 and low-dose nivolumab may enhance immune responses and enable some patients to discontinue antiviral treatment. The trial has fully recruited 121 participants, and further data will be presented at an upcoming conference on November 18, 2024.
Read more →BRNS▲ +10.6%on this news
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Biotherapeutics plc (NASDAQ: BRNS) provided a corporate update and financial results for Q3 2024, showcasing progress in clinical trials for VTP-300 and VTP-1000. Enrollment in the HBV003 trial has completed, with promising interim data anticipated in Q4. The company is also advancing a Phase 1 trial for VTP-1000 aimed at treating celiac disease. Despite progress, Barinthus reported a net loss of $8.1 million and a decrease in cash resources, primarily due to operational expenditures.
Read more →BRNS▲ +10.6%on this news
Document Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results OXFORD, United Kingdom
Barinthus Biotherapeutics plc (NASDAQ BRNS) reported its third quarter 2024 updates, highlighting advancements in its clinical pipeline, particularly the HBV003 trial for chronic hepatitis B and the VTP-1000 trial for celiac disease. The company announced that it completed enrollment in the HBV003 trial and initiated the Phase 1 AVALON trial for VTP-1000, with both programs expecting significant data releases in the upcoming months. Financially, Barinthus reported a net loss of $8.1 million, with total cash decreasing from $117.8 million in the previous quarter, although royalties from previous sales are set to augment their funding through mid-2026.
Read more →BRNSBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting and Attendance at November Conferences
Barinthus Bio has announced that it will be presenting updated clinical data from its chronic hepatitis B program at AASLD 2024. Their late-breaking oral presentation will highlight results from a phase 2b study of VTP-300 combined with low-dose nivolumab. Additionally, the company will participate in various conferences throughout November 2024, including discussions on their ongoing research and immunotherapy candidates targeting infectious diseases and autoimmunity. The company's innovative approach positions it to potentially improve treatment outcomes for patients.
Read more →BRNSBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Barinthus Biotherapeutics plc has successfully completed enrollment for two important clinical trials: the Phase 2b HBV003 focusing on chronic Hepatitis B and the Phase 1 PCA001 for prostate cancer. The HBV003 trial, involving the investigational immunotherapy VTP-300, aims to assess its efficacy as a potential functional cure for chronic Hepatitis B, with preliminary data expected in Q4 2024. Meanwhile, the PCA001 trial intends to evaluate the safety and efficacy of VTP-850 in men with rising PSA levels, with data updates anticipated in H1 2025.
Read more →BRNSBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Barinthus Biotherapeutics plc has announced the initiation of a Phase 1 clinical trial for its investigational immunotherapy candidate, VTP-1000, aimed at treating celiac disease. This trial is noteworthy as celiac disease currently lacks approved therapeutic options. The study will evaluate the safety, tolerability, and pharmacological effects of VTP-1000 in a controlled setting, involving 42 adult participants and a gluten challenge. The development of VTP-1000 highlights Barinthus Bio's commitment to addressing significant unmet medical needs in immunology.
Read more →BRNSBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Biotherapeutics plc (BRNS) reported its financial results for the second quarter of 2024, highlighting significant progress in their Phase 2 clinical trials for VTP-300 targeting hepatitis B virus (HBV) and the upcoming initiation of trials for VTP-1000 in celiac disease. The company announced a strategic prioritization of these programs due to their high probability of success and potential to meet substantial patient needs. However, Barinthus also reported a net loss of $16.9 million and indicated a workforce reduction, reflecting operational adjustments in response to evolving strategic goals.
Read more →BRNSDocument Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results OXFORD, United Kingdom
Barinthus Bio has provided an update on its corporate developments and financial results for the second quarter of 2024. The company has prioritized its HBV and celiac disease programs, driven by positive interim data from the VTP-300 Phase 2 trials. Barinthus Bio plans to initiate the first human clinical trial of VTP-1000 for celiac disease in Q3 2024. Despite a reported net loss of $16.9 million, the company maintains a solid cash position and is focused on advancing its therapeutic candidates.
Read more →BRNSBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Biotherapeutics has announced a strategic prioritization of its pipeline, emphasizing the development of VTP-300 for chronic Hepatitis B and VTP-1000 for celiac disease. This decision follows positive interim data from Phase 2 clinical trials, suggesting that VTP-300 can significantly reduce HBsAg levels in patients. To align resources with this streamlined focus, the company will reduce its workforce by approximately 25%, while expecting to extend its cash runway into the second quarter of 2026. The changes are aimed at enhancing the probability of success for their immunotherapy candidates.
Read more →BRNSDocument Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B In the HBV003 trial, 67% of partic
Barinthus Bio has announced encouraging interim results from two clinical trials involving VTP-300 for chronic hepatitis B therapy. In the HBV003 trial, 67% of participants achieved significant HBsAg declines, indicating the treatment's potential to provide sustained viral suppression. Additionally, the IM-PROVE II trial demonstrated significant differences in HBsAg levels between VTP-300 and placebo groups after treatment. Overall, the trials indicate VTP-300's potential to reshape treatment approaches for chronic hepatitis B, providing hope for patients seeking less lifelong therapy.
Read more →BRNSBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Barinthus Bio announced promising interim results from two clinical trials (HBV003 and IM-PROVE II) involving their treatment VTP-300 for chronic hepatitis B. In these studies, a significant percentage of participants achieved low or undetectable levels of hepatitis B surface antigen (HBsAg) and were able to discontinue standard nucleos(t)ide analogue (NUC) therapy. The results showed that VTP-300 could form part of a functional cure regimen, with many patients maintaining responsiveness beyond treatment. Side effects were generally manageable, with few serious adverse events reported.
Read more →BRNS▲ +6.9%on this news
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Biotherapeutics is set to present updates on its hepatitis B immunotherapeutic candidate VTP-300 at the upcoming EASL Congress 2024. The presentations will include clinical data showing significant reductions in HBsAg levels, indicating potential rates of functional cure. The data builds on prior interim findings and will be presented in both poster and oral formats. The CEO expressed enthusiasm about sharing the company's efforts to combat chronic HBV infections, while acknowledging the global challenges posed by low diagnosis rates and treatment access.
Read more →BRNSDocument Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments OXFORD, United Kingdom
Barinthus Biotherapeutics plc (NASDAQ BRNS) reported its financial results for Q1 2024, highlighting significant progress in its clinical programs. Notably, it received FDA clearance for VTP-1000 to begin Phase 1 trials in celiac disease. Additionally, topline data from the VTP-200 Phase 1b 2 trial indicated encouraging safety outcomes, although clear efficacy improvements were not statistically significant. The company continues to manage its cash runway effectively while facing a net loss and zero revenue this quarter.
Read more →BRNSBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Bio (NASDAQ: BRNS) reported its financial results for the first quarter of 2024, announcing significant progress in its clinical programs. The company received FDA clearance for the IND application for VTP-1000, allowing a first-in-human trial for celiac disease, and provided positive topline data for its VTP-200 HPV study. Despite having a robust cash position of $130 million, Barinthus faced challenges with no revenue and a net loss of $15.5 million for the quarter. Furthermore, the appointment of Dr. Leon Hooftman as Chief Medical Officer is expected to enhance the company's strategy moving forward.
Read more →BRNS▲ +7.3%on this news
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Barinthus Biotherapeutics has appointed Leon Hooftman, M.D., as Chief Medical Officer, effective June 2024. Dr. Hooftman brings significant experience in drug development across several therapeutic areas, including oncology and infectious diseases. His appointment is seen as a strategic move to bolster Barinthus Bio's efforts in advancing their pipeline of T cell immunotherapeutic candidates. The company is focused on developing therapies aimed at providing solutions for chronic infectious diseases and cancer.
Read more →BRNSBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Barinthus Biotherapeutics announced topline data from its Phase 1b/2 APOLLO trial, which evaluated the safety and efficacy of VTP-200 in women with persistent high-risk HPV infections. The trial met its primary safety endpoint, showing that VTP-200 was well-tolerated. Although there were positive trends in clearance rates for hrHPV and cervical lesions in some groups, pooled data indicated no statistically significant improvement versus placebo. Future development options for VTP-200 are now being assessed as further analyses are ongoing.
Read more →BRNSDocument Barinthus Bio Announces Topline Data from Phase 1b 2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections Primary safety endpoint met VTP-200 was generally well-tolerated, with n
Barinthus Bio announced positive topline data from the Phase 1b 2 APOLLO trial for VTP-200, an investigational treatment for persistent high-risk HPV infections. The trial met its primary safety endpoint, with VTP-200 showing good tolerability and no serious adverse events. While positive trends were noted in HPV and cervical lesion clearance rates for the highest dose cohorts, no statistically significant improvements were observed compared to the placebo group. Further analyses are ongoing to explore immunological responses and assess future development options.
Read more →BRNSBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported its financial results for the year ending December 31, 2023, highlighting significant advancements in its clinical programs. The company secured up to $35 million in funding for its MERS program and anticipates a productive 2024 with multiple trial results expected. However, Barinthus also faced a net loss of $73.4 million and a sharp decline in revenue from previous years. The firm has outlined milestones for the coming year, including the initiation of new clinical trials and updates on ongoing studies.
Read more →BRNSDocument Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments OXFORD, United Kingdom
Barinthus Biotherapeutics plc (NASDAQ: BRNS) has reported its financial results for the year ending December 31, 2023, highlighting a productive year with significant clinical developments. The company secured funding from CEPI for its MERS program and shared positive data from its HPV and HBV trials. However, it also showed a notable net loss of $73.4 million and a dramatic drop in revenue to $0.8 million, necessitating careful monitoring of its financial health as it moves forward. Overall, while the clinical progress is promising, the financial results show considerable challenges.
Read more →BRNSBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones Cash runway anticipated to be extended from Q2 2025 to Q4 2025 Data from multiple Phase 1 and 2 clinical trials expected in 20
Barinthus Bio has released a financial update, indicating an extended cash runway until Q4 2025, which is an improvement from the previous Q2 2025 projection. The company anticipates multiple data readouts from its Phase 1 and 2 clinical trials in 2024, including developments in hepatitis B virus and human papillomavirus programs. However, it has deferred the IND application for its HPV cancer candidate, VTP-1100, to maximize resource allocation. The preliminary financial information remains uncertain and may undergo significant changes as the year progresses.
Read more →BRNSNew partnership aims to advance vaccine against MERS coronavirus
Barinthus Biotherapeutics (BRNS) has partnered with CEPI and the University of Oxford to advance the MERS coronavirus vaccine candidate, VTP-500. CEPI will invest up to $34.8 million in this initiative, which aims to accelerate the vaccine's development through Phase II clinical trials. If successful, VTP-500 could become part of an emergency stockpile of 100,000 doses available for rapid deployment during outbreaks. This collaboration builds on successful vaccine technology used for other coronaviruses, enhancing global preparedness against infectious diseases.
Read more →BRNS▲ +13.2%on this news
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD Initial data from the combination of imdusiran and VTP
Barinthus Bio presented interim data from two clinical trials at the AASLD conference, showcasing promising results for its HBV treatment candidates. The Phase 2b HBV003 trial indicated significant HBsAg declines when VTP-300 was combined with low-dose nivolumab. The Phase 2a AB-729-202 trial also reported positive outcomes, with all participants qualifying to stop NUC therapy after receiving imdusiran alongside VTP-300. These findings provide optimistic indications for the potential effectiveness of these treatments in chronic HBV patients.
Read more →BRNS▲ +13.2%on this news
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom
Barinthus Biotherapeutics plc (formerly Vaccitech plc) has announced its financial results for Q3 2023, highlighting a substantial evolution in its corporate identity and strategic focus on T cell immunotherapeutic candidates. The company is preparing to present preliminary data from Phase 2 trials at an upcoming conference. Financially, while R&D expenses increased, the company remains committed to advancing its therapeutic pipeline across various diseases. Additionally, shareholders approved a resolution to allow for greater share allotment without pre-emption rights, potentially enhancing their capital structure.
Read more →BRNSVaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer New Corporate Brand to be Unveiled at AAS
Barinthus Biotherapeutics, formerly known as Vaccitech, has announced its rebranding to better reflect its transition into T cell immunotherapy for chronic infectious diseases, autoimmunity, and cancer. The company will unveil its new identity at the AASLD Liver Meeting 2023 while also presenting data from its Phase 2 Hepatitis B trials involving the investigational candidate VTP-300. The rebranding signifies Barinthus's ambition to evolve beyond its origins in vaccine development and explore broader therapeutic possibilities. This transition aims to better align the company's goals with its novel treatment technologies, intended to improve patient outcomes significantly.
Read more →BRNSVaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom
Vaccitech plc reported its financial results for the second quarter of 2023, highlighting significant clinical milestones achieved for its lead programs, VTP-300 and VTP-200. The company has extended its cash runway into 2025, showcasing its operational efficiency. Vaccitech is poised to announce interim data from its ongoing Phase 2 trials later this year. However, the firm faces rising research and development expenses and an increasing accumulated deficit, posing challenges for its financial health.
Read more →BRNSVaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone
Vaccitech plc announced positive final data from its Phase 1b/2 HBV002 study, which evaluates VTP-300 in adults with chronic Hepatitis B. Results showed significant and durable reductions in Hepatitis B Surface Antigen (HBsAg) among participants, particularly those with lower baseline HBsAg levels. The data will be presented at the EASL Congress in Vienna, with implications for enhancing rates of functional cures for chronic Hepatitis B. The study's findings underscore the potential of VTP-300 as a critical component in treating this widespread virus.
Read more →BRNSVaccitech Reports First Quarter 2023 Financial
Vaccitech has reported a positive first quarter for 2023, highlighting significant clinical advancements in their hepatitis B and HPV programs and the addition of Dr. Nadge Pelletier as Chief Scientific Officer. The company has achieved important milestones with its lead candidates, demonstrating promising safety and efficacy. With a focus on maintaining momentum, Vaccitech anticipates further data updates on its hepatitis B program throughout the year. Overall, the financial results underscore a commitment to addressing critical unmet medical needs.
Read more →BRNSVaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments OXFORD, United Kingdom
Vaccitech plc reported its full-year financial results for 2022, detailing an active year of advancing clinical trials and expanding its research capabilities. The company completed enrollment in three clinical trials and initiated three new trials, alongside opening new laboratories in the US and UK. With anticipated data readouts in 2023 for various programs, Vaccitech aims to strengthen its position in the immunotherapy field. However, like many biopharma companies, it faces potential risks related to product development and economic factors.
Read more →BRNSVaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments OXFORD, United Kingdom
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments United Kingdom, November 10, 2022 - Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Compan
Read more →BRNSVaccitech Promotes Gemma Brown as Chief Financial Officer OXFORD, United Kingdom
Vaccitech Promotes Gemma Brown as Chief Financial Officer United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announ
Read more →BRNSVaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Oxford, United Kingdom
Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments United Kingdom, August 9, 2022 - Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company's re
Read more →BRNSVaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered,
Read more →BRNSVaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments Oxford, United Kingdom
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments United Kingdom, May 11, 2022 - Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's rece
Read more →BRNSVaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom
Reports Full-Year 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom, March 25, 2022 -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company's recent co
Read more →BRNSVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines A conference call and webcast will be held on December 14, 2021, at 8:30 a.m. EST (1:30 p.m. GMT). The webcast link and presentation can be found on the
Read more →BRNSVaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom
Third Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom, November 12, 2021 -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of the Company's rec
Read more →BRNSVaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom
Second Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom, August 12, 2021 -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company's recent c
Read more →BRNSVaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom
First Quarter 2021 Financial Results and Recent Corporate Developments Oxford, United Kingdom, June 14, 2021 -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the tr
Read more →Competitive Position
How BRNS ranks across every disease it competes inCompetitive Position is a premium feature
See how BRNS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial